North America T Cell Therapy Market Forecast to 2030
North America T Cell Therapy Market Forecast to 2030 – Regional Analysis – by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing Number of T-Cell Therapy Approvals Fuels the North America T Cell Therapy Market
Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of cell therapy. Globally, cell therapies are widely adopted owing to the availability FDA approved products. Following is the list of T-cell therapy products approved by FDA in recent years:
• For instance, in June 2022, Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).
• In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.
• In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
• In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.
• In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.
Therefore, the increasing number of approvals for T-cell therapies is fueling the North America T cell therapy market growth.
North America T Cell Therapy Market Overview
The T-cell therapy market in North America is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period due to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players. Also, with an increase in clinical studies in CAR T-cell therapies, the market in North America is expected to grow during the forecast period. According to CDC, 1,603,844 new cancer cases were reported and 602,347 people died in the US in 2020. An estimated 184,720 people in the US will be diagnosed with leukemia, lymphoma, or myeloma in 2023.
Tisagenlecleucel (KymriahTM, Novartis, Morris Plains, NJ, US) and axicabtagene ciloleucel (YescartaTM, Gilead Sciences Canada, El Segundo, CA, US) were the first two CAR T-cells commercially available and approved in Canada by Health Canada in 2018 and 2019, respectively. Both are second-generation anti-CD19 CAR T-cells, approved for adult patients with r/r DLBCL, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. Moreover, Canadian-Led Immunotherapies in Cancer-01 (CLIC-01) is the first to introduce CAR T-cell therapy in Canada. It uses a different kind of cell manufacturing that unveils less expensive and more equitable treatment. The Queen Elizabeth II Health Sciences Centre in Halifax became the first facility in Atlantic Canada to offer CAR T-cell therapy locally as of March 2022. Prior to this, Nova Scotia patients who were recommended for this highly personalized cancer medicine had to travel outside the country to receive the treatment. The program was made possible with a government investment of US$ 6.7 million annually. Thus, the rising cancer cases and initiative by the government fuel the T-cell therapy market in North America.
North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
North America T Cell Therapy Market Segmentation
The North America T cell therapy market is segmented into modality , therapy type, indication, and country.
Based on modality, the North America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.
Based on therapy type, the North America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.
Based on indication, the North America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.
Based on country, the North America T cell therapy market is segmented into the US, Canada, and Mexico. The US dominated the North America T cell therapy market share in 2022.
Bluebird Bio Inc, Bristol-Myers Squibb Co, Cartesian Therapeutics Inc, Gilead Sciences Inc, Innovent Biologics Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the North America T cell therapy market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Publishing status: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ research, the North America T cell therapy market was valued at US$ 1,645.52 million in 2022 and is expected to reach US$ 5,329.75 million by 2030, registering a CAGR of 15.8% from 2022 to 2030. Rising number of CAR T-Cell therapies in clinical trials and growing burden of cancer are among the critical factors attributed to the North America T cell therapy market expansion.
The current landscape for CAR T-cell therapies across the globe is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain. In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL. JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL. Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL). ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity—adverse events commonly associated with CAR T-cell treatment. Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the North America T-cell therapy market.
On the contrary, side-effects of CAR T-cell therapy hampers on the growth of North America T cell therapy market.
Based on modality, the North America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held 90.1% market share in 2022, amassing US$ 1,482.36 million. It is projected to garner US$ 4,908.11 million by 2030 to expand at 16.1% CAGR during 2022-2030.
Based on therapy type, the North America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held 93.5% share of North America T cell therapy market in 2022, amassing US$ 1,538.47 million. It is projected to garner US$ 5,025.67 million by 2030 to expand at 15.9% CAGR during 2022-2030.
Based on indication, the North America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held 93.5% share of North America T cell therapy market in 2022, amassing US$ 1,538.47 million. It is projected to garner US$ 5,025.67 million by 2030 to expand at 15.9% CAGR during 2022-2030.
Based on country, the North America T cell therapy market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.8% share of North America T cell therapy market in 2022. It was assessed at US$ 1,378.27 million in 2022 and is likely to hit US$ 4,582.90 million by 2030, exhibiting a CAGR of 16.2% during 2022-2030.
Key players operating in the North America T cell therapy market are Bluebird Bio Inc, Bristol-Myers Squibb Co, Cartesian Therapeutics Inc, Gilead Sciences Inc, Innovent Biologics Inc, Janssen Global Services LLC, and Novartis AG, among others.
May 2022: Novartis declared that the US Food and Drug Administration (FDA) has approved Kymriah (Tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America T cell therapy market
o Highlights key in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in North America T cell therapy market , thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 North America T Cell Therapy Market, by Country (US$ Million)
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America T Cell Therapy Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Growing Burden of Cancer Worldwide
4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:
5. T Cell Therapy Market – North America Market Analysis
5.1 North America T Cell Therapy Market Revenue (US$ Mn), 2022 – 2030
6. North America T Cell Therapy Market – Revenue and Forecast to 2030 – by Modality.
6.1 Overview
6.2 North America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
6.3.1 Overview
6.3.2 Research: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
6.4.1 Overview
6.4.2 Commercialized: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7. North America T Cell Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
7.1 Overview
7.2 North America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
7.3.1 Overview
7.3.2 CAR T-cell Therapy: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
7.4.1 Overview
7.4.2 T-cell Receptor (TCR)-based: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8. North America T Cell Therapy Market – Revenue and Forecast to 2030 – by Indication.
8.1 Overview
8.2 North America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
8.3.1 Overview
8.3.2 Hematologic Malignancies: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.3.3 North America T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
8.4.1 Overview
8.4.2 Solid Tumor: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. North America T Cell Therapy Market – Country Analysis
9.1 Overview
9.1.1.1 North America T Cell Therapy Market, by Country
9.1.1.2 US
9.1.1.2.1 US: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.2.2 US: North America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.2.3 US: North America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.2.4 US: North America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.2.4.1 US: North America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.3 Canada
9.1.1.3.1 Canada: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.3.2 Canada: North America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.3.3 Canada: North America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.3.4 Canada: North America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.3.4.1 Canada: North America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.4 Mexico
9.1.1.4.1 Mexico: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.4.2 Mexico: North America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.4.3 Mexico: North America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.4.4 Mexico: North America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.4.4.1 Mexico: North America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10. T Cell Therapy Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Legend Biotech Corp
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Janssen Global Services LLC
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Gilead Sciences Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Bristol-Myers Squibb Co
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Novartis AG
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Cartesian Therapeutics Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Innovent Biologics Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. North America T Cell Therapy Market Segmentation
Table 2. North America T Cell Therapy Market, by Hematological Malignancies – Revenue and Forecast to 2030 (US$ Million)
Table 3. US: North America T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 5. US: North America T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada: North America T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada: North America T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada: North America T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: North America T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 11. Mexico: North America T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 12. Mexico: North America T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. Mexico: North America T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico: North America T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 15. Recent Organic Growth Strategies in T Cell Therapy Market
Table 16. Recent Inorganic Growth Strategies in the T Cell Therapy Market
Table 17. Glossary of Terms, North America T Cell Therapy Market
LIST OF FIGURES
Figure 1. North America T Cell Therapy Market Segmentation, By Country
Figure 2. North America T Cell Therapy Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America T Cell Therapy Market Revenue (US$ Mn), 2022 – 2030
Figure 5. North America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. North America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. North America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: North America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America T Cell Therapy Market, by Key Country – Revenue (2022) (US$ Million)
Figure 15. North America T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 16. US: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Canada: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. Mexico: North America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Growth Strategies in T Cell Therapy Market
The List of Companies – North America T Cell Therapy Market
1. Bluebird Bio Inc
2. Bristol-Myers Squibb Co
3. Cartesian Therapeutics Inc
4. Gilead Sciences Inc
5. Innovent Biologics Inc
6. Janssen Global Services LLC
7. Novartis AG
You must be logged in to post a review.
Reviews
There are no reviews yet.